Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment
Type 2 diabetes mellitus (T2DM), a major driver of mortality worldwide, is more likely to develop other cardiometabolic risk factors, ultimately leading to diabetes-related mortality. Although a set of measures including lifestyle intervention and antidiabetic drugs have been proposed to manage T2DM...
Main Authors: | Liyang Jia, Shiqiong Huang, Boyu Sun, Yongguang Shang, Chunsheng Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1149256/full |
Similar Items
-
Editorial: Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
by: Jian-Quan Luo, et al.
Published: (2023-09-01) -
Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance
by: Lavinia Curini, et al.
Published: (2021-09-01) -
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment
by: Hui-Qing Chen, et al.
Published: (2022-01-01) -
The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review
by: Silvia Peretti, et al.
Published: (2022-12-01) -
Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome
by: Davide Leardini, et al.
Published: (2022-12-01)